Collagen biostimulators have become central tools in modern aesthetic medicine. However, products often grouped under the same “biostimulator” label differ significantly in mechanism of action, tissue depth and clinical indication.
Selecting the appropriate product is not a marketing decision — it is a clinical one. This guide outlines how to choose between PLLA, CaHA, polynucleotides and HA biorevitalisers based on mechanism, patient profile and treatment objectives.
What Is a Biostimulator?
A true collagen biostimulator induces neocollagenesis through controlled biological stimulation, typically via:
- foreign-body response
- fibroblast activation
- scaffold-based collagen induction
This distinguishes classic biostimulators such as PLLA and CaHA from regenerative agents like polynucleotides or HA biorevitalisers, which primarily act on dermal quality and extracellular matrix (ECM) remodelling rather than deep structural collagen induction.¹–⁴
Understanding this distinction is essential for proper sequencing and expectation management.
Four Product Families — and Why They Are Not Interchangeable
1. PLLA (Poly-L-Lactic Acid) – e.g. Sculptra
Mechanism: Controlled foreign-body reaction leading to type I and III collagen induction.¹
Depth: Subdermal / supraperiosteal planes.
Best for: Diffuse volume loss, structural laxity, post-weight-loss facial deflation.
Timeline: Gradual onset; peak effect at approximately 3–6 months; long duration.
PLLA is indicated when long-term structural remodelling is required rather than immediate contour correction.
2. CaHA (Calcium Hydroxylapatite) – e.g. Radiesse
Mechanism: Bioresorbable microsphere scaffold combined with fibroblast stimulation and collagen/elastin production.²
Depth: Deep dermis to subdermal.
Best for: Jawline definition, lower-face laxity, hand rejuvenation.
Timeline: Immediate contour improvement plus progressive tissue tightening.
CaHA is preferred when both structural support and visible short-term contour enhancement are needed.
3. Polynucleotides (PN / PDRN)
Mechanism: Activation of purinergic A2A receptors, stimulation of fibroblast proliferation, angiogenesis and ECM repair.³
Depth: Dermal / superficial subdermal.
Best for: Thin, UV-damaged, reactive or hormonally affected skin; periorbital area.
Timeline: Progressive improvement across several sessions.
Polynucleotides are regenerative agents focused on skin quality rather than volumisation.
4. HA Biorevitalisers (Hybrid HA Complexes)
Mechanism: High-concentration hyaluronic acid complexes supporting ECM remodelling, hydration and elasticity.⁴
Depth: Deep dermis / subcutaneous.
Best for: Skin density, elasticity and overall “skin envelope” improvement without significant volumisation.
Timeline: Visible improvement after 1–2 sessions in many clinical series.
HA biorevitalisers should not be positioned as direct equivalents of PLLA or CaHA.
Comparative Overview: Mechanism, Depth and Clinical Role
| Product Family | Mechanism of Action | Tissue Level | Primary Clinical Objective | Typical Timeline |
| PLLA (e.g. Sculptra) | Controlled foreign-body reaction with induction of type I/III collagen | Subdermal / supraperiosteal | Structural remodelling, diffuse volume loss | Gradual (3–6 months) |
| CaHA (e.g. Radiesse) | Microsphere scaffold + fibroblast stimulation | Deep dermis / subdermal | Contour support + tightening | Immediate + progressive |
| Polynucleotides (PN / PDRN) | A2A receptor activation, fibroblast proliferation, ECM repair | Dermal / superficial subdermal | Skin quality, thin/reactive or UV-damaged skin | Progressive (session-based) |
| HA Biorevitalisers (Hybrid HA Complexes) | High-concentration HA complexes promoting ECM remodelling and elasticity | Deep dermis / subcutaneous | Density and elasticity improvement without volumisation | Visible after 1–2 sessions |
How to Choose a Biostimulator in Clinical Practice
Rather than starting with age, begin with three structured questions:
1. Is the dominant issue volume loss or skin quality?
Volume loss dominant → consider PLLA or CaHA.
Skin quality deterioration dominant → consider polynucleotides or HA biorevitalisers.
Mixed presentation → plan sequential combination therapy.
This distinction prevents overtreatment and improves predictability.⁵
2. What is the biological skin age?
Dermal thickness, hydration, photo-damage and systemic factors (e.g. smoking, metabolic disease) significantly influence collagen synthesis and ECM turnover.⁶
Protocol intensity and frequency should reflect tissue biology rather than chronological age.
3. What timeline does the patient expect?
PLLA requires months for full collagen deposition. CaHA provides partial immediate improvement with continued stimulation. PN and HA biorevitalisers offer gradual quality enhancement.
Misaligned expectations remain one of the most common causes of perceived treatment failure despite technically correct injections.⁵
Example: Practical Treatment Plan for Skin Quality Restoration
Ideal candidate:
Age 40–55, primary concern = density, dullness, early laxity; preserved overall volume.
Phase 1 (Weeks 0–8): Regeneration
Two to three sessions of polynucleotides at 3–4-week intervals to improve dermal quality and microcirculation.³
Phase 2 (Weeks 8–12): Biorevitalisation
One to two sessions of HA biorevitaliser to enhance elasticity and ECM remodelling.⁴
Phase 3 (Month 3+): Escalation if Needed
Introduce PLLA for diffuse collagen induction or CaHA for contour-focused tightening if structural deficits become more evident.¹²
This phased approach allows assessment at each stage and reduces the risk of early overtreatment.
Common Clinical Mistakes
Expecting lifting from HA biorevitalisers.
Using CaHA in thin dermis without appropriate dilution.
Inadequate PLLA reconstitution and post-treatment massage.
Combining multiple stimulators in a single session without staged assessment.
Consensus recommendations emphasise correct product preparation, dilution protocols and patient education to minimise adverse events and optimise outcomes.¹²
Conclusion
PLLA, CaHA, polynucleotides and HA biorevitalisers represent distinct therapeutic mechanisms. They are not interchangeable, even if they are often grouped under the same commercial category.
Accurate patient qualification, realistic timeline setting and mechanism-based product selection are central to predictable outcomes and long-term patient satisfaction.
For licensed professionals, the Fräya portfolio includes curated collagen biostimulators and regenerative injectables supported by technical documentation and protocol guidance via practitioner account access at frayamedsupply.com.
References (selected clinical sources)
Vleggaar D, Fitzgerald R. Poly-L-lactic acid in facial rejuvenation.
de Almeida AT et al. Calcium hydroxylapatite fillers in facial rejuvenation.
Clinical and pharmacological data on PDRN / polynucleotides in regenerative medicine.
Clinical data on hybrid HA complexes and ECM remodelling.
Expert reviews on treatment planning and patient selection in collagen biostimulation.
Studies on smoking, systemic disease and collagen metabolism.
